Company intelligence / Profile preview
Zhejiang Hangyu Pharmaceutical
Hangzhou, Zhejiang, Chinaapi-made.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Zhejiang Hangyu Pharmaceutical has an active clinical pipeline with at least five programs spanning oncology, cardiovascular/metabolic disorders, nephrology, and infectious disease. Its lead asset JMKX‑001899 targeting KRAS G12C mutant non-small cell lung cancer has reached Phase 3. Two additional assets are in Phase 2 for heart failure and hyperphosphatemia. The company also provides contract research services including pharmaceutical R&D, formulation development, quality research/control services, clinical study management and regulatory registration support for chemical and peptide drugs.
- Therapeutic areas
- OncologyEndocrinologyNeurologyCardiovascularNephrologyInfectious Diseases
- Modalities
- Small moleculePeptide
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Zhejiang Hangyu Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zhejiang Hangyu Pharmaceutical.